## SEQUENCE LISTING

```
<110> PAUL, SUDHIR
      NISHIYAMA, YASUHIRO
<120> PROTEOLYTIC AND COVALENT ANTIBODIES
<130> UTEX0012UPCT-US
<140> 10/581,294
<141> 2003-03-26
<150> 60/458,063
<151> 2003-03-26
<150> 60/534,689
<151> 2004-01-08
<160> 18
<170> PatentIn Ver. 3.3
<210> 1
<211> 4
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 1
Ile Glu Gly Arg
  1
<210> 2
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      6x His tag
<400> 2
His His His His His
  1
                  5
<210> 3
<211> 4
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
      peptide
```

```
<400> 3
Ala Ala Pro Phe
 1
<210> 4
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 4
Tyr Leu Asn Ser Ile Leu Asn
<210> 5
<211> 16
<212> PRT
<213> Human immunodeficiency virus type 2
Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala
                                      10
                                                          15
<210> 6
<211> 4
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 6
Ile Glu Ala Arq
 1
<210> 7
<211> 10
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
      peptide
Thr Glu Lys Leu Trp Val Thr Val Tyr Tyr
```

```
<210> 8
<211> 12
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 8
Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Asn
<210> 9
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 9
Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly
<210> 10
<211> 4
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 10
Cys Ser Cys Cys
 1
<210> 11
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 11
His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg Leu Arg Lys Gln
                                     10
Met Ala Val
```

```
<210> 12
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
<400> 12
Lys Tyr Leu Asn Ser Ile Leu Asn
<210> 13
<211> 28
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 13
His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg Leu Arg Lys Gln
                                     10
Met Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn
             20
<210> 14
<211> 42
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 14
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
                 5
                                     10
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
Gly Leu Met Val Gly Gly Val Val Ile Ala
<210> 15
<211> 27
<212> PRT
<213> Artificial Sequence
```

```
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 15
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn
<210> 16
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 16
Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala
<210> 17
<211> 26
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
     peptide
<400> 17
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
                 5
                                     10
Gly Leu Met Val Gly Gly Val Val Ile Ala
             20
<210> 18
<211> 4
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
     4x His tag
<400> 18
His His His His
 1
```